Pathological complete response induced by neoadjuvant treatment using BRAF and MEK inhibitors in a patient with unresectable BRAF V600E-mutant malignant melanoma of the gallbladder

Pathological complete response induced by neoadjuvant treatment using BRAF and MEK inhibitors in a patient with unresectable BRAF V600E-mutant malignant melanoma of the gallbladder

Zhou Yu,1 Elisa Quiroz,2 Yulei Shen,3 Ishmael A Jaiyesimi1 1Department of Hematology and Oncology, William Beaumont Hospital, Oakland University – William Beaumont School of Medicine, Royal Oak, MI, USA; 2Department of Internal Medicine, William Beaumont Hospital, Oakland University &...

Full description

Bibliographic Details
Main Authors:	Yu Z, Quiroz E, Shen Y, Jaiyesimi IA
Format:	Article
Language:	English
Published:	Dove Medical Press 2018-12-01
Series:	OncoTargets and Therapy
Subjects:	melanoma gallbladder BRAF V600E mutation neoadjuvant targeted therapy
Online Access:	https://www.dovepress.com/pathological-complete-response-induced-by-neoadjuvant-treatment-using--peer-reviewed-article-OTT

Similar Items

BRAF V600E MUTATIONS IN METASTATIC MELANOMA - CASE REPORT
by: Ivana Inić, et al.
Published: (2014-09-01)

BRAF Mutation (V600E) Prevalence in Mexican Patients Diagnosed with Melanoma
by: Priscilla Denise Zepeda-Lopez, et al.
Published: (2016-04-01)

ANÁLISE DA MUTAÇÃO V600E DO GENE BRAF EM MELANOMAS CUTÂNEOS PRIMÁRIOS
by: Sugita, Juliana Sayuri
Published: (2016)

Vemurafenib in Chinese patients with BRAF V600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study
by: Lu Si, et al.
Published: (2018-05-01)

The role of BRAF V600 mutation in melanoma
by: Ascierto Paolo A, et al.
Published: (2012-07-01)

Oncogenic BRAF(V600E) Induces Clastogenesis and UVB Hypersensitivity
by: Dennis A. Simpson, et al.
Published: (2015-06-01)

Implicaciones diagnósticas, terapéuticas y pronósticas de la mutación BRAF V600E en melanomas cutáneos
by: Alberto José Piamo Morales
Published: (2019-05-01)

Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for <i>BRAF</i>-Mutant Melanoma
by: Omid Hamid, et al.
Published: (2019-10-01)

Clinico-economic analysis of PD-1 inhibitors and combinations of BRAF and MEK inhibitors for the treatment of metastatic melanoma with a BRAF V600 gene mutation
by: D. Yu. Belousov, et al.
Published: (2018-07-01)

Low BRAF V600 mutation prevalence in primary skin nodular melanoma in Indonesia: a real-time PCR detection among Javanese patients
by: Hanggoro Tri Rinonce, et al.
Published: (2019-12-01)

Case Report: Rechallenge With BRAF and MEK Inhibitors in Metastatic Melanoma: A Further Therapeutic Option in Salvage Setting?
by: Anna Stagno, et al.
Published: (2021-05-01)

Inhibition of mitochondrial respiration prevents BRAF-mutant melanoma brain metastasis
by: Terje Sundstrøm, et al.
Published: (2019-04-01)

Current Advances in the Treatment of BRAF-Mutant Melanoma
by: Hima Patel, et al.
Published: (2020-02-01)

Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells
by: Eszter Molnár, et al.
Published: (2018-05-01)

Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy
by: Yu Kanemaru, et al.
Published: (2019-07-01)

Safety and Tolerability of BRAF Inhibitor and BRAF Inhibitor-Based Combination Therapy in Chinese Patients With Advanced Melanoma: A Real World Study
by: Xing Liu, et al.
Published: (2021-04-01)

Inhibitors of pan PI3K signaling synergize with BRAF or MEK inhibitors to prevent BRAF-mutant melanoma cell growth
by: Melanie eSweetlove, et al.
Published: (2015-06-01)

Indirect Comparison of Combined BRAF and MEK Inhibition in Melanoma Patients with Elevated Baseline Lactate Dehydrogenase
by: Valerie Glutsch, et al.
Published: (2020-06-01)

Dabrafenib: a new opportunity for the treatment of BRAF V600-positive melanoma
by: Banzi M, et al.
Published: (2016-05-01)

Določanje mutacije V600E v genu BRAF
by: Petra Škerl, et al.
Published: (2010-12-01)

Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy
by: Raphael Reinhard, MD, et al.
Published: (2018-03-01)

Efficacy of BRAF and MEK Inhibition in Patients with BRAF-Mutant Advanced Melanoma and Germline CDKN2A Pathogenic Variants
by: Francesco Spagnolo, et al.
Published: (2021-05-01)

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma
by: Ernesto Rossi, et al.
Published: (2019-04-01)

Dual Targeting of BRAF and mTOR Signaling in Melanoma Cells with Pyridinyl Imidazole Compounds
by: Veronika Palušová, et al.
Published: (2020-06-01)

Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with TwoState-of-the-Art Techniques
by: Nicola L. Schoenewolf, et al.
Published: (2012-06-01)

Identification of coexistence of BRAF V600E mutation and EZH2 gain specifically in melanoma as a promising target for combination therapy
by: Huan Yu, et al.
Published: (2017-12-01)

BRAF V600 Mutation Profile of Metastatic Melanoma in the Thrace Region of Turkey
by: Nuray CAN, et al.
Published: (2018-05-01)

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing
by: Gulietta M. Pupo, et al.
Published: (2017-05-01)

Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial
by: Lili Mao, et al.
Published: (2021-08-01)

Immunohistochemical BRAF V600E Expression and Intratumor BRAF V600E Heterogeneity in Acral Melanoma: Implication in Melanoma-Specific Survival
by: Takamichi Ito, et al.
Published: (2020-03-01)

Immunological effects of BRAF+MEK inhibition
by: Paolo A. Ascierto, et al.
Published: (2018-09-01)

Encorafenib/binimetinib for the treatment of BRAF-mutant advanced, unresectable, or metastatic melanoma: design, development, and potential place in therapy
by: Sun J, et al.
Published: (2018-12-01)

Electrochemotherapy with bleomycin is effective in BRAF mutated melanoma cells and interacts with BRAF inhibitors
by: Dolinsek Tanja, et al.
Published: (2016-09-01)

Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab
by: Justin C. Moser, et al.
Published: (2019-12-01)

BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors
by: Karisa C. Schreck, et al.
Published: (2019-08-01)

Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma
by: Sara Bjursten, et al.
Published: (2019-11-01)

Arthralgia Induced by BRAF Inhibitor Therapy in Melanoma Patients
by: Martin Salzmann, et al.
Published: (2020-10-01)

BRAF non-V600E more frequently co-occurs with IDH1/2 mutations in adult patients with gliomas than in patients harboring BRAF V600E but without a survival advantage
by: Wei Wang, et al.
Published: (2021-05-01)

Characterization and Clinical Utility of <i>BRAF</i><sup>V600</sup> Mutation Detection Using Cell-Free DNA in Patients with Advanced Melanoma
by: Piotr Rutkowski, et al.
Published: (2021-07-01)

Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant <it>BRAF</it> and wildtype <it>PTEN</it> status
by: Byron Sara A, et al.
Published: (2012-10-01)